FDA warns about 'contamination' in a certain cancer treatment solution
The Food and Drug Administration (FDA) issued a warning on Monday, March 18, urging hospitals, healthcare facilities, professionals, and the general public to cease the use of Methotrexate 100 milligram/milliliter (mg/ml) solution for intramuscular (IM) and intravenous (IV) injections.

It explained that methotrexate, which is manufactured by Bruck Pharma Private Limited, India, and distributed by Nelpa Life Sciences, Inc. in the country, serves as a crucial treatment for cancer and other severe illnesses that do not respond to regular medications.
However, the FDA found a big problem with contamination in a batch of the drug with the code I23J001A and confirmed that it has "Pseudomonas aeruginosa," a harmful bacteria.
It highlighted that the infection with Pseudomonas aeruginosa in the bloodstream can be really serious, even causing death.
The agency also pointed out that when giving this drug to patients with weakened immune systems, it's important to have really careful quality checks to stop any contamination problems.
Given the gravity of the situation, the FDA mandated an immediate stop to the use and dispensing of all available batches until further notice.
It underscored the importance of drug establishments implementing rigorous risk management plans and promptly addressing safety breaches.
Moreover, the agency is actively investigating the accountability of drug establishments in ensuring product quality and safety, with penalties upcoming where warranted.